Hidradenitis Suppurativa: Where We Are and Where We Are Going
Open accessThe DOI matches its Crossref record; 151 of the 152 references it cites were found in a registry or an index.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. It is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture and immune responses. Innate pro-inflammatory cytokines (e.g., IL-1β, and TNF-α); mediators of activated T helper (Th)1 and Th17 cells (e.g., IFN-γ, and IL-17); and effector mechanisms of neutrophilic granulocytes, macrophages, and plasma cells are involved. On the other hand, HS lesions contain anti-inflammatory mediators (e.g., IL-10) and show limited activity of Th22 cells. The inflammatory vicious circle finally results in pain, purulence, tissue destruction, and scarring. HS pathogenesis is still enigmatic, and a valid animal model for HS is currently not available. All these aspects represent a challenge for the development of therapeutic approaches, which are urgently needed for this debilitating disease. Available treatments are limited, mostly off-label, and surgical interventions are often required to achieve remission. In this paper, we provide an overview of the current knowledge surrounding HS, including the diagnosis, pathogenesis, treatments, and existing translational studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Progression leads to follicular rupture, with release of keratin, hair shaft fragments, and microbial products into the dermis [38,39].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of dermal tunnels is particularly useful in established diseases and distinguishes hidradenitis suppurativa from simple folliculitis or isolated abscesses.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more advanced lesions, the most characteristic and frequent histological finding is the presence of epithelium-lined sinus tracts or dermal tunnels, usually associated with chronic inflammation, granulation tissue, fibrosis, and scarring [38].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ruptured follicles trigger a dense mixed inflammatory infiltrate composed of neutrophils, lymphocytes, plasma cells, macrophages, and foreign-body giant cells. These are frequently seen in early lesions.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hidradenitis suppurativa is a chronic inflammatory disease characterized by painful nodules, abscesses, scarring, and a complex molecular and cellular landscape [38].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [38]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180 · cited 1×
“In addition, a dysregulation of tryptophan catabolism (with overactivation of the kynurenine pathway and consequent stimulation of cytokines by inflammatory cell infiltrates) and of an aryl hydrocarbon receptor (AHR) (with impaired production of bacteria-derived AHR agonists and decreased incidence of AHR ligand-produ…”
BackgroundEuropean S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093 · cited 4×
“No unrestricted recommendation can be given for the use of conventional immunosuppressant or immunomodulatory drugs including prednisolone [103], dapsone [104], retinoids [105], and ciclosporin [106], amongst others, as there is little or conflicting evidence for their efficacy [63,98].”
BackgroundInfluentialTwo Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 807
Revuz, J. E., Canoui-Poitrine, F., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., Poli, F., Faye, O., Roujeau, J. C., Bonnelye, G., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.020 · Cited by 627
Sabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
Sartorius, K., Emtestam, L., Jemec, G. B. E., & Lapins, J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09198.x · Cited by 525 · cited 3×
“Still today, the Hurley staging and the Sartorius scoring, together with HS Physician Global Assessment systems are the most commonly used assessment tools [22,23].”
BackgroundMethodZouboulis, C. C., Tzellos, T., Kyrgidis, A., Jemec, G. B. E., Bechara, F. G., Giamarellos‐Bourboulis, E. J., Ingram, J. R., Kanni, T., Karagiannidis, I., Martorell, A., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15748 · Cited by 493
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492 · cited 1×
“Independent of the duration and severity of HS, all patients should follow basic therapeutic measures, including self-education about the disease, pain management, maintaining high hygiene standards, cessation of smoking, and losing weight, amongst others [1,96].”
Backgroundvan der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 472 · cited 3×
“sion of NRLP3 as well as IL-1β were detected in HS lesions [75,77,78].”
Backgroundγ-Secretase Gene Mutations in Familial Acne Inversa
Wang, B., Yang, W., Wen, W., Sun, J., Su, B., Liu, B., Ma, D., Lv, D., Wen, Y., Qu, T., et al. (2010) · Science · doi:10.1126/science.1196284 · Cited by 451
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
Schlapbach, C., Hänni, T., Yawalkar, N., & Hunger, R. E. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.07.010 · Cited by 425 · cited 1×
“Coherently, high levels of IL-23 (which drives IL-17 production) have been also found in HS lesional skin [74,88].”
BackgroundAlikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.068 · Cited by 399 · cited 4×
“However, it is a β-lactamic carbapenem with no anti-inflammatory proprieties and is reserved as third-line therapy for a single six-week course as rescue therapy or during surgical planning [98,101].”
BackgroundInfluentialTopical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa
Jemec, G. B. E., & Wendelboe, P. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70272-5 · Cited by 338
Revuz, J. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03356.x · Cited by 336 · cited 1×
“According to the modified Dessau definition, three diagnostic criteria should be matched: presence of typical lesions, typical locations, and chronicity [10].”
MethodA short history of sweat gland biology
Wilke, K., Martin, A., Terstegen, L., & Biel, S. S. (2007) · International Journal of Cosmetic Science · doi:10.1111/j.1467-2494.2007.00387.x · Cited by 334
Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Kelly, G., Hughes, R., McGarry, T., Born, M., Adamzik, K., Fitzgerald, R., Lawlor, C., Tobin, A. M., Sweeney, C. M., & Kirby, B. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14075 · Cited by 306 · cited 3×
“sion of NRLP3 as well as IL-1β were detected in HS lesions [75,77,78].”
BackgroundTopical Treatment of Hidradenitis Suppurativa with Clindamycin
Clemmensen, O. J. (1983) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1983.tb02150.x · Cited by 270 · cited 1×
“Topical antibiotics and antiseptics are frequently used, although there is little evidence for efficacy [97,98].”
BackgroundGener, G., Canoui-Poitrine, F., Revuz, J. E., Faye, O., Poli, F., Gabison, G., Pouget, F., Viallette, C., Wolkenstein, P., & Bastuji-Garin, S. (2009) · Dermatology · doi:10.1159/000228334 · Cited by 265 · cited 1×
“, tetracyclines, clindamycin, rifampicin) are considered first-line therapy according to guidelines and expert opinions, although HS is not primarily an infectious disease, and none of them are approved by the Federal Drug Agency (FDA) or the European Medicines Agency (EMA) for the treatment of HS [1,63,95,99].”
BackgroundZouboulis, C. C., Bechara, F. G., Dickinson‐Blok, J. L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A. B., Kirby, B., Martorell, A., Podda, M., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15233 · Cited by 259 · cited 3×
“nodules, and scar tissue [95] (Table 1).”
BackgroundWolk, K., Warszawska, K., Hoeflich, C., Witte, E., Schneider-Burrus, S., Witte, K., Kunz, S., Buss, A., Roewert, H. J., Krause, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903907 · Cited by 254 · cited 2×
“Elevated levels of IL-17 have been observed in HS lesions [87,88].”
BackgroundHidradenitis suppurativa: from pathogenesis to diagnosis and treatment
Napolitano, M., Megna, M., Timoshchuk, E., Patruno, C., Balato, N., Fabbrocini, G., & Monfrecola, G. (2017) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s111019 · Cited by 253 · cited 4×
“In this scenario, bacterial colonization is considered a secondary pathogenic factor that can worsen HS [2,4].”
BackgroundInfluentialSelf-citationCanoui-Poitrine, F., Le Thuaut, A., Revuz, J. E., Viallette, C., Gabison, G., Poli, F., Pouget, F., Wolkenstein, P., & Bastuji-Garin, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.472 · Cited by 248 · cited 1×
“Three clinical subtypes of HS have been described: axillary-mammary, follicular, and gluteal [18].”
BackgroundWitte-Händel, E., Wolk, K., Tsaousi, A., Irmer, M. L., Mößner, R., Shomroni, O., Lingner, T., Witte, K., Kunkel, D., Salinas, G., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.018 · Cited by 239 · cited 2×
“sion of NRLP3 as well as IL-1β were detected in HS lesions [75,77,78].”
Backgroundvan der Zee, H. H., Prens, E. P., & Boer, J. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.12.018 · Cited by 235
Vigne, S., Palmer, G., Martin, P., Lamacchia, C., Strebel, D., Rodriguez, E., Olleros, M. L., Vesin, D., Garcia, I., Ronchi, F., et al. (2012) · Blood · doi:10.1182/blood-2012-06-439026 · Cited by 218 · cited 1×
“Moreover, IL-36 cytokines, which belong to the IL-1 family, are able to mediate Th1 and Th17 responses [89,90].”
BackgroundLaffert, M. V., Helmbold, P., Wohlrab, J., Fiedler, E., Stadie, V., & Marsch, W. C. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00915.x · Cited by 205 · cited 1×
“The perifollicular inflammatory cellular infiltrate causes abscess formation, leading to the destruction of the pilosebaceous unit [2,4,63,64].”
BackgroundKimball, A. B., Sobell, J. M., Zouboulis, C. C., Gu, Y., Williams, D. A., Sundaram, M., Teixeira, H. D., & Jemec, G. B. E. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13216 · Cited by 202 · cited 2×
“In addition, the HS Clinical Response (HiSCR), defined as the reduction in at least 50% of total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count relative to baseline, is used mainly to assess treatment effects in trials [24].”
MethodThe clinical genetics of hidradenitis suppurativa revisited
Von Der Werth, J. M., Williams, H. C., & Raeburn, J. A. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03476.x · Cited by 195 · cited 1×
“[39] reviewed 14 of the surviving probands in a subsequent study, confirming autosomal dominant pattern of HS.”
BackgroundBlok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14338 · Cited by 193
New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes
van der Zee, H. H., & Jemec, G. B. E. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.07.047 · Cited by 192
Aetiology and pathogenesis of hidradenitis suppurativa
Wolk, K., Join‐Lambert, O., & Sabat, R. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19556 · Cited by 192 · cited 3×
“Additionally, TNF-α acts as an upstream mediator of T cell differentiation into T helper (Th)1, and Th17 cells which produce interferon (IFN)-γ and IL-17, respectively [1,79].”
BackgroundInfluentialUltrasound In-Depth Characterization and Staging of Hidradenitis Suppurativa
Wortsman, X., Moreno, C., Soto, R., Arellano, J., Pezo, C., & Wortsman, J. (2013) · Dermatologic Surgery · doi:10.1111/dsu.12329 · Cited by 182 · cited 2×
“Wortsman and colleagues proposed a sonographic scoring system for HS (SOS-HS) that combined the results of parameters included in Hurley’s classification with the relevant sonographic findings [28].”
BackgroundMethodIntrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa
Hotz, C., Boniotto, M., Guguin, A., Surenaud, M., Jean-Louis, F., Tisserand, P., Ortonne, N., Hersant, B., Bosc, R., Poli, F., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.036 · Cited by 179 · cited 2×
“It is worthy to note that IL-22 production is enhanced by Notch signaling, which is defective in some HS patients [92,94].”
BackgroundShalom, G., Freud, T., Harman‐Boehm, I., Polishchuk, I., & Cohen, A. D. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13777 · Cited by 176 · cited 1×
“The association between HS and obesity has been well established, with numerous studies demonstrating greater disease severity with increasing body mass index (BMI) [45,46].”
BackgroundPink, A. E., Simpson, M. A., Desai, N., Dafou, D., Hills, A., Mortimer, P., Smith, C. H., Trembath, R. C., & Barker, J. N. W. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.162 · Cited by 161 · cited 2×
“However, evidence is growing that γ-Secretase mutations underpin only a minority of cases of HS, even in those individuals with a positive family history [41,42].”
BackgroundEfficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis Suppurativa
Join‐Lambert, O., Coignard-Biehler, H., Jaïs, J., Guet‐Revillet, H., Poirée, S., Fraitag, S., Jullien, V., Ribadeau-Dumas, F., Thèze, J., Guern, A. L., et al. (2010) · Dermatology · doi:10.1159/000321716 · Cited by 151
Bacterial biofilm in chronic lesions of hidradenitis suppurativa
Ring, H. C., Bay, L., Nilsson, M., Kallenbach, K., Miller, I. M., Saunte, D. M., Bjarnsholt, T., Tolker-Nielsen, T., & Jemec, G. B. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15007 · Cited by 151 · cited 2×
“further sustaining chronic inflammation which guides HS [70].”
BackgroundGuet-Revillet, H., Jais, J.-P., Ungeheuer, M.-N., Coignard-Biehler, H., Duchatelet, S., Delage, M., Lam, T., Hovnanian, A., Lortholary, O., Nassif, X., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix285 · Cited by 148 · cited 1×
“Particularly, Staphylococcus lugdunensis seems to dominate in HS nodules and abscesses, followed by a polymicrobial anaerobic microflora mainly comprising prevotella and porphyromonas, but also milleri group streptococci, and actinomycetes [66,67].”
BackgroundEvidence of genetic factors in hidradenitis suppurativa
Fitzsimmons, J. S., Guilbert, P., & Fitzsimmons, E. (1985) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1985.tb02037.x · Cited by 148 · cited 1×
“Fitzsimmons and colleagues [37,38] took up the story in 1984, publishing two case series and concluding that the pattern of inheritance suggested a single gene disorder inherited as an autosomal dominant trait.”
BackgroundBacterial Pathogens Associated with Hidradenitis Suppurativa, France
Guet-Revillet, H., Coignard-Biehler, H., Jais, J.-P., Quesne, G., Frapy, E., Poirée, S., Le Guern, A.-S., Le Flèche-Matéos, A., Hovnanian, A., Consigny, P.-H., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2012.140064 · Cited by 148
Melnik, B. C., & Plewig, G. (2013) · Experimental Dermatology · doi:10.1111/exd.12098 · Cited by 144 · cited 1×
“Melnik and Plewig [65] recently proposed the concept of HS as an auto-inflammatory disease characterized by dysregulation of the gamma-secretase/Notch pathway which has a key role in maintaining the inner and outer root sheath of the hair follicle and skin appendages.”
Backgroundvan der Zee, H. H., Laman, J. D., de Ruiter, L., Dik, W. A., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10698.x · Cited by 138
Kirby, J. S., Thorlacius, L., Villumsen, B., Ingram, J. R., Garg, A., Christensen, K. B., Butt, M., Esmann, S., Tan, J. K. L., & Jemec, G. B. E. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18692 · Cited by 130 · cited 1×
“Therefore, specific QoL tools have been developed and validated for HS: HiSQOL [30], HSQoL-24 [31], and patient-reported outcome (PRO) questionnaires [32].”
MethodDapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients
Yazdanyar, S., Boer, J., Ingvarsson, G., Szepietowski, J. C., & Jemec, G. B. E. (2011) · Dermatology · doi:10.1159/000329023 · Cited by 121 · cited 2×
“or immunomodulatory drugs including prednisolone [103], dapsone [104], retinoids”
BackgroundHidradenitis Suppurativa: Causes, Features, and Current Treatments.
Vinkel, C., & Thomsen, S. F. (2018) · Europe PMC (PubMed Central) · Cited by 118
Join‐Lambert, O., Coignard-Biehler, H., Jaïs, J., Delage, M., Guet‐Revillet, H., Poirée, S., Duchatelet, S., Jullien, V., Hovnanian, A., Lortholary, O., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv361 · Cited by 114 · cited 1×
“Combined with surgery, optimized antibiotic treatments may be promising in severe HS [100].”
BackgroundHazen, P. G., & Hazen, B. P. (2009) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2009.01427.x · Cited by 111
Gao, M., Wang, P., Cui, Y., Yang, S., Zhang, Y., Lin, D., Zhang, K.-Y., Liang, Y., Sun, L., Yan, K., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700272 · Cited by 109 · cited 1×
“[40] identified a locus of interest on chromosome 1p21.”
BackgroundmTORC1 signaling and IL‐17 expression: Defining pathways and possible therapeutic targets
Ren, W., Yin, J., Duan, J., Liu, G., Tan, B., Yang, G., Wu, G., Bazer, F. W., Peng, Y., & Yin, Y. (2015) · European Journal of Immunology · doi:10.1002/eji.201545886 · Cited by 105
Montero‐Vílchez, T., Díaz‐Calvillo, P., Rodríguez-Pozo, J.-Á., Cuenca‐Barrales, C., Martínez‐López, A., Arias‐Santiago, S., & Molina‐Leyva, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136709 · Cited by 105
Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review
Sivanand, A., Gulliver, W. P. F., Josan, C. K., Alhusayen, R. O., & Fleming, P. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419874412 · Cited by 98 · cited 1×
“Clinicians may consider incorporating weight loss and the elimination of potential dietary triggers [52], as adjunct interventions, into the management plan.”
BackgroundThe critical role of macrophages in the pathogenesis of hidradenitis suppurativa
Shah, A., Alhusayen, R. O., & Amini‐Nik, S. (2017) · Inflammation Research · doi:10.1007/s00011-017-1074-y · Cited by 97 · cited 1×
“All of these events produce an increased amount of pro-inflammatory cytokines including TNF-α which positively correlates with disease severity [80].”
BackgroundNaik, H. B., Jo, J., Paul, M., & Kong, H. H. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.445 · Cited by 94
Martorell, A., Jfri, A. H., Koster, S., Gomez-Palencia, P., Solera, M., Alfaro‐Rubio, A., Hueso, L., & Sanz‐Motilva, V. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16183 · Cited by 90 · cited 1×
“Recently, it was suggested to distinguish between a follicular subtype and an inflammatory phenotype, which is usually associated with a worse course of HS [20].”
BackgroundIL-36 cytokines are increased in acne and hidradenitis suppurativa
Caprio, R. D., Balato, A., Caiazzo, G., Lembo, S., Raimondo, A., Fabbrocini, G., & Monfrecola, G. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1769-5 · Cited by 88 · cited 1×
“Moreover, IL-36 cytokines, which belong to the IL-1 family, are able to mediate Th1 and Th17 responses [89,90].”
BackgroundSelf-citationThe ABC of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions
Lipsker, D. M., Séverac, F., Freysz, M., Sauleau, E., Boer, J., Emtestam, L., Matusiak, Ł., Prens, E. P., Velter, C., Lenormand, C., et al. (2016) · Dermatology · doi:10.1159/000443878 · Cited by 84 · cited 1×
“Commonly, patients experience pain, malodor, a burning sensation, and an itch [11].”
BackgroundWhat is hidradenitis suppurativa?
Lee, E. Y., Alhusayen, R. O., Lansang, P., Shear, N. H., & Yeung, J. (2017) · Europe PMC (PubMed Central) · Cited by 84
Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa
Del Duca, E., Morelli, P., Bennardo, L., Di Raimondo, C., & Nisticò, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228436 · Cited by 84 · cited 4×
“Immune cells and keratinocyte-mediated products are widely accepted as key players in HS pathogenesis [73].”
BackgroundInfluentialIngram, J. R., Woo, P. N., Chua, S., Ormerod, A. D., Desai, N., Kai, A., Hood, K., Burton, T., Kerdel, F. A., Garner, S. E., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14418 · Cited by 83
Hidradenitis suppurativa and smoking: A systematic review and meta-analysis
Acharya, P., & Mathur, M. C. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.10.044 · Cited by 83 · cited 1×
“Cigarette smoking is another trigger factor associated with HS [58].”
BackgroundBettoli, V., Naldi, L., Cazzaniga, S., Zauli, S., Atzori, L., Borghi, A., Capezzera, R., Caproni, M., Cardinali, C., DeVita, V., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13864 · Cited by 81 · cited 2×
“HS patients are at increased risk of developing other disorders, such as high cholesterol, high blood pressure, and diabetes [46,48].”
BackgroundSelf-citationSurgical treatment of hidradenitis suppurativa
Jörg Bohn, H. S. (2001) · Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery · doi:10.1080/028443101750523230 · Cited by 81
Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin.
Rose, R. F., Goodfield, M. J. D., & Clark, S. M. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2005.01983.x · Cited by 81
Inflammatory Mechanisms in Hidradenitis Suppurativa
Kelly, G. A., & Prens, E. P. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.08.004 · Cited by 81
Quality of Life in Hidradenitis Suppurativa: An Update
Chernyshov, P. V., Finlay, A. Y., Tomas-Aragones, L., Poot, F., Sampogna, F., Marrón, S. E., Земсков, С., ABENI, D. D., Tzellos, T., Szepietowski, J. C., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18116131 · Cited by 81
Crowley, J., Mekkes, J. R., Zouboulis, C. C., Scheinfeld, N. S., Kimball, A. B., Sundaram, M., Gu, Y., Okun, M. M., & Kerdel, F. A. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13122 · Cited by 80
A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa
Hessam, S., Scholl, L., Sand, M. S., Schmitz, L., Reitenbach, S., & Bechara, F. G. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.5890 · Cited by 80
Bettoli, V., Manfredini, M., Massoli, L., Carillo, C., Barozzi, A., Amendolagine, G., Ruina, G., Musmeci, D., Libanore, M., Curtolo, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15332 · Cited by 78 · cited 1×
“Moreover, the identification of pathogenic microbes should be evaluated and it could be useful in the therapeutic management, even if a primary infection is not the principal cause of HS [17].”
BackgroundEsmann, S., Dufour, D., & Jemec, G. B. E. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09773.x · Cited by 77 · cited 1×
“HS may less frequently occur in the lower abdomen, suprapubic, retroauricular, nape, eyelids, and scalp [14,15].”
BackgroundDiagnosing Hidradenitis Suppurativa
Revuz, J. E., & Jemec, G. B. E. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.08.009 · Cited by 77
van Straalen, K. R., Prens, E. P., Willemsen, G. A. H. M., Boomsma, D. I., & van der Zee, H. H. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3630 · Cited by 77 · cited 1×
“In a recent cross-sectional study [44] on self-reported HS conducted from 2011 to 2016, data were collected from twins participating in the surveys of the nationwide Netherlands Twin Register.”
MethodPosch, C., Itzinger-Monshi, B., Quint, T., Vujic, I., Lilgenau, N., & Rappersberger, K. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.055 · Cited by 76
Target molecules for future hidradenitis suppurativa treatment
Zouboulis, C. C., Frew, J. W., Giamarellos‐Bourboulis, E. J., Jemec, G. B. E., del Mármol, V., Marzano, A. V., Nikolakis, G. D., Sayed, C. J., Tzellos, T., Wolk, K., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14338 · Cited by 76
IL-26, a Cytokine With Roles in Extracellular DNA-Induced Inflammation and Microbial Defense
Larochette, V., Miot, C., Poli, C., Beaumont, E., Roingeard, P., Fickenscher, H., Jeannin, P., & Delneste, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00204 · Cited by 75 · cited 2×
“It leads to the production of pro-inflammatory cytokines through its receptor (IL-10R2 and IL-20R1) but it can also bind to cell-free DNA and subsequently activate TLRs pathways [91].”
BackgroundFamilial hidradenitis suppurativa: evidence in favour of single gene transmission.
Fitzsimmons, J. S., Fitzsimmons, E., & Gilbert, G. L. (1984) · Journal of Medical Genetics · doi:10.1136/jmg.21.4.281 · Cited by 73 · cited 1×
“Fitzsimmons and colleagues [37,38] took up the story in 1984, publishing two case series and concluding that the pattern of inheritance suggested a single gene disorder inherited as an autosomal dominant trait.”
BackgroundGarg, A., Birabaharan, M., & Strunk, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.014 · Cited by 72 · cited 1×
“In particular, a higher prevalence of diabetes mellitus (DM) among patients with HS compared to control subjects was observed [49], with prevalences ranging from 7.”
BackgroundResearch Techniques Made Simple: Murine Models of Human Psoriasis
Hawkes, J. E., Aðalsteinsson, J. A., Gudjonsson, J. E., & Ward, N. L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.10.013 · Cited by 71 · cited 1×
“Therefore, xenograft models could be particularly interesting for HS research, as they could overcome these obstacles and open up new perspectives for a better understanding of complex inflammatory skin diseases as they did for psoriasis, and alopecia areata [141,142].”
BackgroundHidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis
Bui, T., Silva‐Hirschberg, C., Torres, J., & Armstrong, A. W. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.042 · Cited by 69 · cited 1×
“3) [51] times that of the control individuals, respectively.”
BackgroundAdipokines are dysregulated in patients with hidradenitis suppurativa
Malara, A., Hughes, R., Jennings, L., Sweeney, C. M., Lynch, M., Awdeh, F., Timoney, I., Tobin, A., Lynam-Loane, K., Tobin, L. M., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15904 · Cited by 68 · cited 1×
“In fact, adipokine balance in HS is shifted towards increased expression of pro-inflammatory resistin and leptin, contributing to the augmentation of inflammatory processes in the skin of patients with HS [47].”
BackgroundAssociation of Hidradenitis Suppurativa With Body Image
Schneider‐Burrus, S., Jost, A., Peters, E. M. J., Witte-Haendel, E., Sterry, W., & Sabat, R. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.6058 · Cited by 68
An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis
Tricarico, P. M., Boniotto, M., Genovese, G., Zouboulis, C. C., Marzano, A. V., & Crovella, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00892 · Cited by 68
Hessam, S., Sand, M. S., Skrygan, M., Gambichler, T., & Bechara, F. G. (2016) · Inflammation · doi:10.1007/s10753-016-0492-2 · Cited by 67
Pain management in patients with hidradenitis suppurativa
Horváth, B., Janse, I. C., & Sibbald, G. R. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.07.046 · Cited by 66
Monfrecola, G., Balato, A., Caiazzo, G., Vita, V. D., Caprio, R. D., Donnarumma, M., Lembo, S., & Fabbrocini, G. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13233 · Cited by 64 · cited 2×
“Interestingly, mTOR signaling has been implicated in promoting adipogenesis and lipogenesis, as well as the accumulation of triacylglycerols in sebaceous glands [53,54].”
BackgroundResultSelf-citationSuccessful treatment of hidradenitis suppurativa with acitretin
Hogan, D. J., & Light, M. J. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)80251-2 · Cited by 64
Guenin‐Macé, L., Morel, J., Doisne, J., Schiavo, A., Boulet, L., Mayau, V., Gonçalves, P., Duchatelet, S., Hovnanian, A., Bondet, V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140598 · Cited by 62 · cited 1×
“In addition, a dysregulation of tryptophan catabolism (with overactivation of the kynurenine pathway and consequent stimulation of cytokines by inflammatory cell infiltrates) and of an aryl hydrocarbon receptor (AHR) (with impaired production of bacteria-derived AHR agonists and decreased incidence of AHR ligand-produ…”
BackgroundInterobserver variability of clinical scores in hidradenitis suppurativa is low
Sartorius, K., Killasli, H., Heilborn, J. D., Jemec, G. B. E., Lapins, J., & Emtestam, L. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09715.x · Cited by 62 · cited 2×
“Still today, the Hurley staging and the Sartorius scoring, together with HS Physician Global Assessment systems are the most commonly used assessment tools [22,23].”
MethodJemec, G. B. E., Okun, M. M., Forman, S. B., Gulliver, W. P., Prens, E. P., Mrowietz, U., Armstrong, A. W., Geng, Z., Gu, Y., Williams, D., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17919 · Cited by 62
Schneider, A. M., Cook, L. C., Zhan, X., Banerjee, K., Cong, Z., Kawasawa, Y. I., Gettle, S. L., Longenecker, A. L., Kirby, J. S., & Nelson, A. M. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.06.151 · Cited by 62 · cited 2×
“Bacterial dysbiosis is present at the skin’s surface, in the follicle, and at distinct body sites in HS compared with normal skin with the decrease in the relative abundance of skin commensals, and the increase of opportunistic anaerobic pathogens being found in HS with respect to healthy skin [68,69].”
BackgroundHidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta‐analysis
Phan, K. H., Charlton, O., & Smith, S. D. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.13922 · Cited by 61
Acne and hidradenitis suppurativa
Pink, A., Anzengruber, F., & Navarini, A. A. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16231 · Cited by 59 · cited 4×
“Indeed, 95% of early HS lesions present hyperkeratosis, occlusion of the follicular unit and an associated perifolliculitis [4].”
BackgroundInfluentialSecukinumab and hidradenitis suppurativa: Friends or foes?
Marasca, C., Megna, M., Balato, A., Balato, N., Napolitano, M., & Fabbrocini, G. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.12.002 · Cited by 59
Self-citationRibero, S., Ramondetta, A., Fabbrocini, G., Bettoli, V., Potenza, C., Chiricozzi, A., Licciardello, M., Marzano, A. V., Bianchi, L., Rozzo, G., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17178 · Cited by 58
Self-citationThe Hidradenitis Suppurativa Priority Setting Partnership
Ingram, J. R., Abbott, R. A., Ghazavi, M., ALEXANDROFF, A. B., McPhee, M., Burton, T., & Clarke, T. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13163 · Cited by 57 · cited 1×
“The question “To what extent is HS caused by genetic factors?” was placed in the top 10 most important uncertainties from a short list of 55 HS uncertainties in a priority setting partnership conducted for HS [35].”
BackgroundKusaba, H., Ghosh, P., Derin, R., Buchholz, M., Sasaki, C., Madara, K., & Longo, D. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m405204200 · Cited by 54
Vossen, A. R. J. V., Ardon, C. B., van der Zee, H. H., Lubberts, E., & Prens, E. P. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17641 · Cited by 53
Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review
Choi, F. D., Lehmer, L. M., Ekelem, C., & Mesinkovska, N. A. (2019) · International Journal of Dermatology · doi:10.1111/ijd.14691 · Cited by 52
Kimball, A. B., Sundaram, M., Banderas, B. F., Foley, C., & Shields, A. L. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1341614 · Cited by 48 · cited 1×
“Therefore, specific QoL tools have been developed and validated for HS: HiSQOL [30], HSQoL-24 [31], and patient-reported outcome (PRO) questionnaires [32].”
MethodBraunberger, T. L., Nartker, N. T., Nicholson, C. L., AL-NAHHAS, A. M., Parks‐Miller, A., Hanna, Z., Jayaprakash, R., Ramesh, M. S., Rambhatla, P. V., & Hamzavi, I. H. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14036 · Cited by 46
Scala, E., Caprio, R. D., Cacciapuoti, S., Caiazzo, G., Fusco, A., Tortorella, E., Fabbrocini, G., & Balato, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17854 · Cited by 45 · cited 4×
“Among Th17 cytokines, IL-26 has also been found to increase in the plasma and skin of HS patients [88].”
BackgroundInfluentialSelf-citationIngram, J. R., Wood, M., John, B., Butler, R., & Anstey, A. V. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12048 · Cited by 44 · cited 1×
“However, evidence is growing that γ-Secretase mutations underpin only a minority of cases of HS, even in those individuals with a positive family history [41,42].”
BackgroundBryant, A. E., Bayer, C. R., Aldape, M. J., & Stevens, D. L. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000160 · Cited by 44 · cited 1×
“However, NSAIDs decrease immunity and have been associated with infection onset and/or worse outcomes [56,57].”
BackgroundThe Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities
Bettoli, V., Pasquinucci, S., Caracciolo, S., Piccolo, D., Cazzaniga, S., Fantini, F., Binello, L., Pintori, G., & Naldi, L. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13687 · Cited by 44 · cited 1×
“Since diagnosis of HS may typically be delayed for years, in order to enhance a correct diagnosis, other factors should be investigated; above all, a family history of HS and history of other follicular occlusion diseases [16].”
BackgroundCurrent and future treatment of hidradenitis suppurativa
van Straalen, K. R., Schneider‐Burrus, S., & Prens, E. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16768 · Cited by 43
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
Chiricozzi, A., Faleri, S., Franceschini, C., Caro, R. D. C., Chimenti, S., & Bianchi, L. (2015) · PubMed · Cited by 42
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa
Megna, M., Ruggiero, A., Guida, A. D., Patrì, A., Fabbrocini, G., & Marasca, C. (2020) · Dermatologic Therapy · doi:10.1111/dth.13756 · Cited by 40
Self-citationYang, J., Wang, L., Huang, Y., Liu, K., Lu, C., Si, N., Wang, R., Liu, Y., & Zhang, X. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0722-8 · Cited by 39
Nomura, Y., Nomura, T., Suzuki, S., Takeda, M., Mizuno, O., Ohguchi, Y., Abe, R., Murata, Y., & Shimizu, H. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.01.013 · Cited by 38 · cited 1×
“A Japanese study has also suggested that a pathogenic γ-Secretase mutation may be insufficient to produce the HS phenotype [43].”
BackgroundHidradenitis suppurativa: infection, autoimmunity, or both?
Constantinou, C. A., Fragoulis, G., & Nikiphorou, E. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19895488 · Cited by 38 · cited 4×
“A positive family history was noted in approximately one-third of HS patients [3,5].”
BackgroundInfluentialUnderstanding the Relationship Between Smoking and Hidradenitis Suppurativa.
Mokoš, Z. B., Miše, J., Balić, A., & Marinović, B. (2020) · PubMed · Cited by 37
Kerdel, F., Azevedo, F. A., Don, C. K., Don, F. A., Fabbrocini, G., & Kerdel, F. A. (2019) · PubMed · Cited by 37
Self-citationOrgan-on-Chip Technology: Current State and Future Developments
Kodzius, R., Schulze, F., Gao, X., & Schneider, M. R. (2017) · Genes · doi:10.3390/genes8100266 · Cited by 36 · cited 1×
“Until research may become independent of patient biopsies by using human-like organs printed on chips and controlled by microfluidic systems [148], current cell culture and explant approaches will be further improved and tailored to these research questions.”
BackgroundSebaceous gland: Milestones of 30‐year modelling research dedicated to the “brain of the skin”
Zouboulis, C. C., Yoshida, G. J., Wu, Y., Xia, L., & Schneider, M. R. (2020) · Experimental Dermatology · doi:10.1111/exd.14184 · Cited by 36
Severe vulval apocrine acne successfully treated with prednisolone and isotretinoin
Fearfield, & Staughton (1999) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.1999.00451.x · Cited by 33 · cited 2×
“or immunomodulatory drugs including prednisolone [103], dapsone [104], retinoids”
BackgroundMontaudié, H., Seitz‐Polski, B., Cornille, A., Benzaken, S., Lacour, J. ‐., & Passeron, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.036 · Cited by 32
Knaysi, G. A. (1968) · JAMA · doi:10.1001/jama.1968.03140010021004 · Cited by 32
Jones, D. R., Banerjee, A., Berger, P. Z., Gross, A., McNish, S., AMDUR, R. L., & Shanmugam, V. K. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1377227 · Cited by 31 · cited 1×
“HS lesions are characterized by a reduced infiltration of IL-22-secreting cells and impaired production of IL-22 by these cells [92,93].”
BackgroundAnti‐ TNF ‐α therapy modulates mTORC 1 signalling in hidradenitis suppurativa
Balato, A., Caiazzo, G., Annunziata, M. C., Marasca, C., Scala, E., Cacciapuoti, S., & Fabbrocini, G. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15160 · Cited by 31
Self-citationA concise clinician’s guide to therapy for hidradenitis suppurativa
Nesbitt, E., Clements, S., & Driscoll, M. S. (2019) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2019.11.004 · Cited by 30
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa
Chiricozzi, A., Bettoli, V., Pità, O. D., Dini, V., Fabbrocini, G., Monfrecola, G., Musumeci, M. L., Parodi, A., Sampogna, F., Pennella, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15122 · Cited by 29 · cited 1×
“Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced [33,34].”
MethodSelf-citationTreatment of hidradenitis suppurativa with certolizumab pegol during pregnancy
Wieser, I., & Alhusayen, R. O. (2020) · International Journal of Dermatology · doi:10.1111/ijd.15286 · Cited by 29
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa*
Cao, Y., Hong, F., Conlon, D., Sidur, L., Smith, K. M., Fang, Y., Cuff, C. A., Kaymakcalan, Z., & Ruzek, M. C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20097 · Cited by 27
Nonsteroidal anti-inflammatory drugs and necrotizing fasciitis
Browne, B. A., Holder, E. P., & Rupnick, L. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.3.265 · Cited by 26 · cited 1×
“However, NSAIDs decrease immunity and have been associated with infection onset and/or worse outcomes [56,57].”
BackgroundThe pharmacology of antibiotic therapy in hidradenitis suppurativa
Marasca, C., Tranchini, P., Marino, V., Annunziata, M. C., Napolitano, M., Fattore, D., & Fabbrocini, G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1762571 · Cited by 25 · cited 3×
“Their mode of action is believed to be immunomodulatory by reducing NFκB activation, resulting in diminished production of pro-inflammatory cytokines [12].”
BackgroundInfluentialSelf-citationCan Animal Skin Diseases or Current Transgenic Mice Serve as a Model for Hidradenitis Suppurativa?
van der Zee, H. H., Laman, J. D., & Prens, E. P. (2012) · Dermatology · doi:10.1159/000339773 · Cited by 23
Emerging medical treatments for hidradenitis suppurativa
Lyons, A. B., Shabeeb, N., Nicholson, C. L., Braunberger, T. L., Peacock, A., & Hamzavi, I. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.009 · Cited by 23
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review
Holm, J. G., Jørgensen, A. R., Yao, Y., & Thomsen, S. F. (2020) · Dermatologic Therapy · doi:10.1111/dth.14494 · Cited by 23
Animal Models for Alopecia Areata: What and Where?
Sundberg, J. P., McElwee, K. J., Brehm, M. A., Su, L., & King, L. E. (2015) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2015.35 · Cited by 21 · cited 1×
“Therefore, xenograft models could be particularly interesting for HS research, as they could overcome these obstacles and open up new perspectives for a better understanding of complex inflammatory skin diseases as they did for psoriasis, and alopecia areata [141,142].”
BackgroundLesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1
Vossen, A. R. J. V., van Straalen, K. R., Florencia, E. F., & Prens, E. P. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.01.023 · Cited by 21
Marasca, C., Marasca, D., Megna, M., Annunziata, M. C., & Fabbrocini, G. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16361 · Cited by 21 · cited 2×
“and their recognition is able to modify a therapeutic approach [29].”
BackgroundSelf-citationRapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report
Eşme, P., Akoğlu, G., & Çalışkan, E. (2020) · Skin Appendage Disorders · doi:10.1159/000511284 · Cited by 21
Yoshida, Y., Oyama, N., Iino, S., Shimizu, C., & Hasegawa, M. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15807 · Cited by 20
Kok, Y., Nicolopoulos, J., & Dolianitis, C. (2021) · Australasian Journal of Dermatology · doi:10.1111/ajd.13559 · Cited by 20
Agut‐Busquet, E., Romaní, J., Ribera, M., & Luelmo, J. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14722 · Cited by 16 · cited 1×
“HS may less frequently occur in the lower abdomen, suprapubic, retroauricular, nape, eyelids, and scalp [14,15].”
BackgroundMarrón, S. E., Gómez-Barrera, M., Tomas-Aragones, L., Díaz, R. M., Vilarrasa, E., Álvarez, M. B. M., & Puig, L. (2019) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2019.02.002 · Cited by 16 · cited 1×
“Therefore, specific QoL tools have been developed and validated for HS: HiSQOL [30], HSQoL-24 [31], and patient-reported outcome (PRO) questionnaires [32].”
MethodPsychosocial impact of hidradenitis suppurativa: a practical guide for clinicians
Weigelt, M. A., Milrad, S. F., Kirby, J. S., & Lev‐Tov, H. A. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1937483 · Cited by 16
Insulin resistance, mTOR and hidradenitis suppurativa
Marasca, C., Balato, A., Annunziata, M. C., Cacciapuoti, S., & Fabbrocini, G. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15271 · Cited by 15
Self-citationMarrón, S. E., Gómez-Barrera, M., Tomas-Aragones, L., Díaz, R. M., Vilarrasa, E., Álvarez, M. B. M., & Puig, L. (2019) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2019.07.014 · Cited by 15
New insights into mechanism of Notch signaling in hidradenitis suppurativa
Scala, E., Balato, A., Marasca, C., Caprio, R. D., Raimondo, A., Cacciapuoti, S., & Fabbrocini, G. (2020) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.18.06083-2 · Cited by 13
Self-citationProfile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes
Deilhes, F., Rouquet, R.-M., Gall, Y., Aquilina, C., Paul, C. F., & Konstantinou, M. P. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16494 · Cited by 13 · cited 1×
“Thus, smoking cessation should be included as part of the therapeutic management of HS patients [60,61].”
BackgroundZouboulis, C. C. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18173 · Cited by 12
Emerging drugs for the treatment of hidradenitis suppurativa
Folkes, A. S., Hawatmeh, F. Z., Wong, A. C., & Kerdel, F. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1787984 · Cited by 11
Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model
Quartey, Q. Q., Miller, R. J., Pinsker, B. L., Okoh, U. J., Shipman, W. D., George, B. A., Nwizu, C. C., Barnes, L. A., Kerns, M. L., Caffrey, J. A., et al. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.14054 · Cited by 10
Fabbrocini, G., Marasca, C., Megna, M., Peris, K., & the HS Quality of Life Study Group (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15821 · Cited by 9 · cited 1×
“Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced [33,34].”
MethodSelf-citationmTORC1 – a potential player in the pathogenesis of hidradenitis suppurativa?
Dmitriev, A., König, A., Lang, V., Diehl, S., Kaufmann, R., Pinter, A., & Buerger, C. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17202 · Cited by 9
Knaysi, G. A., Cosman, B., & Crikelair, G. F. (1968) · PubMed · Cited by 9
Derruau, S., Gobinet, C., Untereiner, V., Sockalingum, G. D., Nassif, A., Viguier, M. A., Piot, O., & Lorimier, S. (2020) · Journal of Biophotonics · doi:10.1002/jbio.202000327 · Cited by 8
Ertapenem para el tratamiento de hidradenitis supurativa: ¿en qué medida lo necesitamos?
Mendes‐Bastos, P., Martorell, A., & Magina, S. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2018.03.012 · Cited by 7 · cited 2×
“However, it is a β-lactamic carbapenem with no anti-inflammatory proprieties and is reserved as third-line therapy for a single six-week course as rescue therapy or during surgical planning [98,101].”
BackgroundSeverity staging of hidradenitis suppurativa: is Hurley classification the answer?
Thorlacius, L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18158 · Cited by 6 · cited 2×
“Indeed, the use of this method in clinical studies may have significant limitations [21].”
MethodErtapenem for the treatment of Hidradenitis suppurativa: how much do we need it?
Mendes‐Bastos, P., Martorell, A., & Magina, S. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2018.06.001 · Cited by 1
Cited by
Roy, T., Boateng, S. T., Uddin, M. B., Banang-Mbeumi, S., Yadav, R. K., Bock, C. R., Folahan, J. T., Siwe-Noundou, X., Walker, A. L., King, J. A., et al. (2023) · Cells · doi:10.3390/cells12121671 · Cited by 161
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
Krueger, J. G., Frew, J. W., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E. P., Reich, K., Cullen, E., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad345 · Cited by 132
Krajewski, P. K., Złotowska, A., & Szepietowski, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216292 · Cited by 82
“…such as IL-1βand TNF-α, along with mediators from activated Th1 and Th17 helper cells (including IFN-γ and IL-17), and effector mechanisms involving neutrophils, and Th17 helper cells (including IFN-γ and IL-17), and effector mechanisms involving neutrophils, macrophages and plasma cells [17–19].”
BackgroundBurden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes
Kimball, A. B., Kirby, J. S., Ingram, J. R., Tran, T., Pansar, I., Ciaravino, V., Willems, D., Lewis-Mikhael, A.-M., Tongbram, V., & Garg, A. (2024) · Dermatology and Therapy · doi:10.1007/s13555-023-01085-w · Cited by 55
“HS can have a profound negative impact on patients’ health-related quality of life (HRQoL), mainly due to the high disease burden resulting from symptoms, delays in diagnosis limited access to appropriate disease management, and disease-related comorbidity profile [2–5].”
BackgroundPathogenesis of Inflammation in Skin Disease: From Molecular Mechanisms to Pathology
Shirley, S. N., Watson, A. E., & Yusuf, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810152 · Cited by 74
“Besides the associated pain and itching, the malodorous purulent discharge from ruptured follicles and the extensive scarring cause social embarrassment and isolation for many patients [55].”
Background
Metadata
- Authors
- Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., & Fabbrocini, G.
- Affiliations
- Karolinska Institutet (SE)
- University of Naples Federico II (IT)
- Division of Dermatology and Venereology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden
- Technical University of Munich (DE)
- Karolinska University Hospital (SE)
- Corresponding author
- Scala, Emanuele
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-08-15
- Volume
- 10
- Issue
- 8
- Pages
- 2094
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8392140
- OpenAlex
- W3195421093
- Semantic Scholar
- 304c292cd74070067b2680ed72014e3741c3c074
- Cited by
- 135
- References
- 152
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 31 · 2023: 27 · 2022: 20 · 2021: 2
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion, cc-by)
- Funders
- Technische Universität München
- Topics
- Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
- Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- hidradenitis suppurativa, pathogenesis, follicular occlusion, apocrine glands, inflammatory cytokines, Th17 cells, Th22 cells, neutrophils, IL-17, TNF-α, IL-10, immune dysregulation, animal models, diagnosis, treatment, surgical treatment, chronic inflammatory skin disease
- MeSH terms
- Anti-Inflammatory Agents, Combined Modality Therapy, Humans, Inflammation, Skin, Biomarkers, Cytokines, Hidradenitis Suppurativa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.